top of page
  • bill3766

High price of Ozempic, other diabetes drugs deprive low-income people of effective treatment

Tandra Cooper Harris and her husband Marcus, both diabetic, struggle to access crucial medications due to supply shortages, insurance hurdles, and high costs. GLP-1 agonists like Ozempic and Trulicity are vital for managing their conditions, but prices set by drugmakers make them unaffordable for many. The situation worsens with supply shortages and insurance restrictions, leaving patients and healthcare providers scrambling for alternatives. Click here for article.

  1. Access Challenges: Tandra and Marcus face obstacles accessing their essential medications due to supply shortages, insurance approval processes, and high out-of-pocket costs.

  2. High Drug Prices: Drugmakers charge exorbitant prices for GLP-1 agonists, making them unaffordable for many patients, especially those with limited incomes.

  3. Supply Shortages: Demand for GLP-1 agonists has surged, leading to supply shortages, exacerbating the challenge of obtaining these medications.

  4. Healthcare Provider Struggle: Healthcare providers like Dr. Rahman and Dr. Addison navigate complex insurance rules and drug availability issues to provide alternative care plans for patients, often compromising on effectiveness due to cost constraints.

5 views0 comments

Commentaires


bottom of page